|
|
|
|
Vitamin D-mediated calcium absorption in patients with clinically stable Crohn's disease: A pilot study
Vitamin D is the critical hormone for intestinal absorption of calcium.Optimal calcium absorption is important for proper mineralization of bone in the prevention of osteoporosis and osteoporotic fractures, among other important functions.
|
|
|
Intensive Statin Use Shows Reduced Risk of Cardiovascular Events in High-Risk Patients
New data from two subanalyses of the Treating to New Targets (TNT) trial showed an increased dose of atorvastatin calcium (Lipitor), lowered cardiovascular events among high-risk patients with both coronary heart disease (CHD) and chronic kidney disease ...
|
|
|
More Evidence That Swings in Blood Pressure Raise Stroke Risk
SUNDAY, March 14 (HealthDay News) --Following on recent, similar research, a large five-year study points to fluctuations in blood pressure over time as a key indicator of stroke risk.In the study, British researchers tracked the health of more than 19,000...
|
|
|
More Evidence That Swings in Blood Pressure Raise Stroke Risk
SUNDAY, March 14 (HealthDay News) --Following on recent, similar research, a large five-year study points to fluctuations in blood pressure over time as a key indicator of stroke risk.In the study, British researchers tracked the health of more than 19,000...
|
|
|
New process patent granted to IIT Madras and MIN for a drug used in dialysis patients with chronic kidney disease
The collaboration between a medical doctor from Madras Institute of Nephrology (MIN) and an organic chemist from IIT Madras has resulted in the development of an improved single stage process for the synthesis of a polymeric phosphate binder and several softer...
|
|
|
More Evidence That Swings in Blood Pressure Raise Stroke Risk
SUNDAY, March 14 (HealthDay News) --Following on recent, similar research, a large five-year study points to fluctuations in blood pressure over time as a key indicator of stroke risk.In the study, British researchers tracked the health of more than 19,000...
|
|
|
Lack of effect of short-term treatment with Amlodipine and Lisinopril on retinal autoregulation in normotensive patients with type 1 diabetes and mild diabetic retinopathy
Purpose: Diabetic retinopathy is characterized by morphological changes in the retina secondary to disturbances in retinal blood flow.It has been shown that antihypertensive treatment has a protective effect on the development of diabetic retinopathy, and...
|
|
|
Kuros Meets Primary Efficacy Endpoint In Phase Iib Study With Kur-111
RESULTS PROVIDE FIRST CLINICAL PROOF OF PRINCIPLE FOR KUROS BIOACTIVE-BIOMATERIAL PRODUCT PLATFORM Zurich, Switzerland, 15th March, 2010 - Kuros Biosurgery AG announced today the results of a Phase IIb clinical trial assessing the potential of KUR-111 (Viz.I...
|
|
|
Cytokinetics In Phase IIa Clinical Trial For ALS Drug- Update
3/19/2010 7:30 PM ET RELATED NEWS Trade CYTK now with TOP MARKET NEWS (RTTNews) - Friday, Cytokinetics, Inc.(CYTK: News ) revealed opening of a Phase IIa 'Evidence of Effect' clinical trial of CK-2017357 for patients with amyotrophic lateral sclerosis, the...
|
|
|
Mechanism of the Synergistic Effect of Amiodarone and Fluconazole in Candida albicans [Article]
The antiarrhythmic drug amiodarone has been found to have fungicidal activity.In S. cerevisiae , its antifungal activity is mediated by calcium overload stress, which leads to a rapid nuclear accumulation of the calcineurin-regulated transcription...
|
|
|
Imaging Epicardial Adipose Tissue Predicts Heart Diseases
Cardiology - Cardiology The layer of fat around the heart, imaging epicardial adipose tissue, provides extra information compared with standard diagnostic techniques such as coronary artery calcium scoring, say scientists.The size of the layer of fat...
|
|
|
Abdominal CT scans may help reveal patients at higher heart disease risk
Researchers at Henry Ford Hospital observed 367 patients who underwent an abdominal CT and cardiac catheterization between January 2004 and May 2009.They found that patients had a 58 percent risk of having coronary artery disease with an AAC (abdominal...
|
|
|
2-Abdominal CT scans may help reveal patients at higher heart disease risk
Researchers at Henry Ford Hospital observed 367 patients who underwent an abdominal CT and cardiac catheterization between January 2004 and May 2009.They found that patients had a 58 percent risk of having coronary artery disease with an AAC (abdominal...
|
|
|
AMAG Pharmaceuticals' abstract on ferumoxytol for CKD accepted for presentation at NKF 2010
Shire submits REPLAGAL BLA with the FDAShire plc , the global specialty biopharmaceutical company, today announced that it has submitted a ...Data from recent clinical trial for Caldolor Injection to be presentedCumberland Pharmaceuticals Inc.announced today...
|
|
|
Advances in the treatment of Raynauds phenomenon
Levien TL Raynauds phenomenon is a common condition characterized by vasospasm of the digital arteries and resulting cyanosis and redness.It often does not require pharmacologic management, but in some cases symptoms are severe and pharmacologic management...
|
|
|
Xinfu raise its D-Calcium Pantothenate price
_ Xinfu raise its D-Calcium Pantothenate price.
|
|
|
Moderate-to-high dose vitamin D may reduce CVD risk
MedWire News: A systematic review published in the Annals of Internal Medicine suggests that vitamin D, but not calcium, supplements may prevent cardiovascular disease (CVD).Another review in the same journal suggests healthy people with the lowest...
|
|
|
Copper and calcium uptake in colored hair
Smart KE et al.Nanoscale secondary ion mass spectrometry (NanoSIMS) has been used to locate the calcium and copper within hair that has been treated with a colorant and washed multiple times in tap water containing these ions. Untreated hair is used...
|
|
|
ACC: The Agony of Long-Distance Runners -- Coronary Plaque
Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planner ATLANTA -- A group of elite long-distance runners had less body fat, better lipid profiles,...
|
|
|
Taking blood pressure pills cuts risk of dying
Digg Facebook StumbleUpon Delicious E-Mail to a Friend NEW YORK (Reuters Health) - People with high blood pressure who want to reduce their risk of having a stroke or dying prematurely should get their prescriptions filled and see their doctor regularly.In a...
|
|
|
Azur Pharma announces agreement for Prialt
Azur Pharma this week announced the signing of an agreement to acquire Prialt, an analgesic therapy, from Elan.Prialt is indicated in the United States for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who...
|
|
|
Cytokinetics, Inc. (CYTK) Announces Opening of a Phase IIa 'Evidence of Effect' Clinical Trial of CK-2017357 f
(MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated /quotes/comstock/15*!cytk/quotes/nls/cytk (CYTK 3.25, -0.08, -2.26%) announced today that the company has opened a Phase IIa 'Evidence of Effect' (EoE) clinical trial of CK-2017357 for patients with...
|
|
|
Cytokinetics Announces Opening of a Phase IIa 'Evidence of Effect' Clinical Trial of CK-2017357 for Patients W
ophic Lateral Sclerosis Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the company has opened a Phase IIa 'Evidence of Effect' (EoE) clinical trial of CK-2017357 for patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's...
|
|
|
Cytokinetics Announces Opening of a Phase IIa "Evidence of Effect" Clinical Trial of CK-2017357 for Patients With Amyotrophic Lateral Sclerosis
OUTH SAN FRANCISCO, CAMARKETWIRE Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the company has opened a Phase IIa "Evidence of Effect" (EoE) clinical trial of CK-2017357 for patients with amyotrophic lateral sclerosis (ALS), also known as Lou...
|
|
|
Cytokinetics Announces Opening of a Phase IIa 'Evidence of Effect' Clinical Trial of CK-2017357 for Patients W
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 03/19/10 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the company has opened a Phase IIa 'Evidence of Effect' (EoE) clinical trial of CK-2017357 for patients with amyotrophic lateral sclerosis ...
|
